| Literature DB >> 24578795 |
Young-Shin Chung1, Michael Lee2.
Abstract
Erythritol is a sugar alcohol that is widely used as a natural sugar substitute. Thus, the safety of its usage is very important. In the present study, short-term genotoxicity assays were conducted to evaluate the potential genotoxic effects of erythritol. According to the OECD test guidelines, the maximum test dose was 5,000 μg/plate in bacterial reverse mutation tests, 5,000 μg/ml in cell-based assays, and 5,000 mg/kg for in vivo testing. An Ames test did not reveal any positive results. No clastogenicity was observed in a chromosomal aberration test with CHL cells or an in vitro micronucleus test with L5178Y tk (+/-) cells. Erythritol induced a marginal increase of DNA damage at two high doses by 24 hr of exposure in a comet assay using L5178Y tk (+/-) cells. Additionally, in vivo micronucleus tests clearly demonstrated that oral administration of erythritol did not induce micronuclei formation of the bone marrow cells of male ICR mice. Taken together, our results indicate that erythritol is not mutagenic to bacterial cells and does not cause chromosomal damage in mammalian cells either in vitro or in vivo.Entities:
Keywords: Ames assay; Chromosomal aberration test; Comet assay; Erythritol; Genotoxicity; Micronucleus assay
Year: 2013 PMID: 24578795 PMCID: PMC3936177 DOI: 10.5487/TR.2013.29.4.249
Source DB: PubMed Journal: Toxicol Res ISSN: 1976-8257
Fig. 1.Effect of erythritol on revertant colonies in the Ames assay. Five test strains (TA100, TA1537, TA98, TA1535, and E. coli WP2 uvrA) were exposed to erythritol and incubated for 48 hr. Data are expressed as the mean numbers of colonies ± SD from triplicate plates/concentration.
In vitro chromosomal aberration assay for erythritol
| Conc. (g/ml) | S9 mix | Timesa)(hr) | Aberrant metaphases excluding gaps (%) | Aberrant metaphases including gaps (%) |
|---|---|---|---|---|
|
| ||||
| 6 hr treatment | ||||
| 0 | + | 6-18 | 0.5 b) | 3.0 |
| 1250 | + | 6-18 | 2.0 | 5.0 |
| 2500 | + | 6-18 | 3.5 | 5.5 |
| 5000 | + | 6-18 | 1.5 | 4.5 |
| CPA 5 | + | 6-18 | 23.0** c) | 26.5 |
|
| ||||
| 6 hr treatment | ||||
| 0 | - | 6-18 | 0.0 | 1.0 |
| 1250 | - | 6-18 | 0.0 | 1.5 |
| 2500 | - | 6-18 | 0.0 | 0.5 |
| 5000 | - | 6-18 | 0.0 | 1.5 |
| MMC 0.1 | - | 6-18 | 12.0** | 13.0 |
|
| ||||
| 24 hr treatment | ||||
| 0 | - | 24-0 | 0.5 | 1.0 |
| 1250 | - | 24-0 | 0.5 | 0.5 |
| 2500 | - | 24-0 | 0.0 | 0.5 |
| 5000 | - | 24-0 | 0.0 | 1.0 |
| MMC 0.1 | - | 24-0 | 20.0** | 22.0 |
a)Time, Chemical treatment time-recovery time.
b)Means of duplicate cultures; 100 metaphases were examined per culture.
c)Fisher’s exact test; ** significantly different from the control at p<0.01.
Abbreviation: CPA: cyclophosphamide monohydrate, MMC: mitomycin C.
In vitro micronucleus assay for erythritol
| Conc. (g/ml) | S9 mix | Timesa)(hr) | Mean Micronuclei/1000 cellsb) | Relative cell count (%)c) |
|---|---|---|---|---|
|
| ||||
| 3 hr treatment | ||||
| 0 | + | 3-21 | 18.5 | 100 |
| 1250 | + | 3-21 | 30.0 | 75 |
| 2500 | + | 3-21 | 30.5 | 76 |
| 5000 | + | 3-21 | 26.0 | 67 |
| CPA (5 g/ml) | + | 3-21 | 64.5**d) | 64 |
|
| ||||
| 3 hr treatment | ||||
| 0 | - | 3-21 | 21.0 | 100 |
| 1250 | - | 3-21 | 27.0 | 85 |
| 2500 | - | 3-21 | 29.0 | 83 |
| 5000 | - | 3-21 | 28.0 | 84 |
| MMC (0.125 g/ml) | - | 3-21 | 155.0** | 89 |
| COL (0.2 g/ml) | - | 3-21 | 117.0** | 40 |
|
| ||||
| 24 hr treatment | ||||
| 0 | - | 24-0 | 18.5 | 100 |
| 1250 | - | 24-0 | 28.0 | 116 |
| 2500 | - | 24-0 | 26.5 | 112 |
| 5000 | - | 24-0 | 30.0 | 108 |
| MMC (0.0625 g/ml) | - | 24-0 | 148.0** | 80 |
| COL (0.2 g/ml) | - | 24-0 | 58.5** | 54 |
a)Time, Chemical treatment time-recovery time.
b)2000 cells were examined per culture.
c)RCC = (Cell counts of treated flask/Cell counts of untreated flask) × 100.
d)Fisher’s exact test; **p<0.01.
Abbreviation: RCC, Relative cell count; CPA, cyclophosphamide; MMC, mitomycin C; COL, colchicine.
In vitro comet assay for erythritol
| Conc. (g/ml) | S9 mix | % Tail DNAa) | Olive tail moment | Relative cell count (%)b) |
|---|---|---|---|---|
|
| ||||
| 3 hr treatment | ||||
| 0 | + | 7.86 ± 3.91 | 5.51 ± 3.23 | 100 |
| 1250 | + | 8.84 ± 4.64 | 7.40 ± 6.48 | 100 |
| 2500 | + | 9.00 ± 5.65 | 6.15 ± 5.55 | 84.4 |
| 5000 | + | 8.80 ± 6.87 | 7.19 ± 10.86 | 89.3 |
|
| ||||
| 3 hr treatment | ||||
| 0 | - | 7.41 ± 4.55 | 5.14 ± 5.15 | 100 |
| 1250 | - | 8.40 ± 5.13 | 6.73 ± 7.07 | 76.7 |
| 2500 | - | 9.06 ± 5.25 | 6.93 ± 5.77 | 85.6 |
| 5000 | - | 9.97 ± 5.16* | 7.81 ± 6.66 | 71.2 |
|
| ||||
| 24 hr treatment | ||||
| 0 | - | 6.46 ± 3.85 | 4.41 ± 3.50 | 100 |
| 1250 | - | 7.11 ± 4.95 | 4.29 ± 2.83 | 106.7 |
| 2500 | - | 11.81 ± 6.77** | 10.61 ± 9.01 | 110.6 |
| 5000 | - | 11.89 ± 6.35** | 8.59 ± 6.88 | 97.1 |
|
| ||||
| Positive controls | ||||
| CPA (10 g/ml, 3 hr) | + | 19.29 ± 12.54** | 11.51 ± 6.96 | 54.8 |
| H2O2 (200 M, 30 min) | - | 88.59 ± 5.17** | 78.60 ± 15.37 | 71.1 |
| MMS (0.1 mM, 3 hr) | - | 77.78 ± 6.15** | 48.54 ± 6.15 | 74.0 |
*p<0.05, **p < 0.01, statistically significant vs. negative control according to Kruskal-Wallis test with post-test.
a)100 cells were examined per culture.
b)Viability measured by trypan blue exclusion; expressed as percentage of absorbance of control.
In vivo micronucleus assay for erythritol
| Dose (mg/kg) | No. of animal | MNPCE/2000 PCEs (Mean ± S.D.) | PCE/(PCE + NCE) (Mean ± S.D.) | |
|---|---|---|---|---|
|
| ||||
| Erythritol | 0 | 5 | 2.00 ± 1.58 | 0.47 ± 0.02 |
| 1250 | 5 | 3.20 ± 0.84 | 0.46 ± 0.05 | |
| 2500 | 5 | 2.60 ± 0.89 | 0.44 ± 0.02 | |
| 5000 | 5 | 2.20 ± 1.48 | 0.43 ± 0.00 | |
| MMC | 1 | 5 | 28.60 ± 6.47* | 0.29 ± 0.03 |
*Significantly different from the vehicle control at p<0.05 (Fisher’s exact test).
Abbreviations: PCE: Polychromatic erythrocyte, NCE: Normochromatic erythrocyte, MNPCE: PCE with one or more micronuclei, MMC: mitomycin C (positive control).